Tasly Pharmaceutical Group Co Ltd
SSE:600535

Watchlist Manager
Tasly Pharmaceutical Group Co Ltd Logo
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Watchlist
Price: 14.46 CNY
Market Cap: 21.6B CNY
Have any thoughts about
Tasly Pharmaceutical Group Co Ltd?
Write Note

Tasly Pharmaceutical Group Co Ltd
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tasly Pharmaceutical Group Co Ltd
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Minority Interest
ÂĄ311.9m
CAGR 3-Years
-10%
CAGR 5-Years
-16%
CAGR 10-Years
3%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Minority Interest
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Minority Interest
ÂĄ575.3m
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Minority Interest
ÂĄ564.9m
CAGR 3-Years
-1%
CAGR 5-Years
41%
CAGR 10-Years
5%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Minority Interest
ÂĄ20.9m
CAGR 3-Years
-54%
CAGR 5-Years
-32%
CAGR 10-Years
-16%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tasly Pharmaceutical Group Co Ltd
Glance View

Market Cap
21.6B CNY
Industry
Pharmaceuticals

In the heart of China's bustling pharmaceutical landscape lies Tasly Pharmaceutical Group Co Ltd, a company intricately blending traditional herbal wisdom with cutting-edge scientific innovation. Founded in 1994, this enterprise has carved a niche in the competitive world of healthcare by focusing on Traditional Chinese Medicine (TCM) while also expanding into chemical medicine and biological drugs. Tasly's ecosystem thrives on the research, development, manufacturing, and marketing of its diverse product portfolio, which includes patent medicines, herbal injections, and health supplements. The crown jewel in its product lineup is the Compound Danshen Dripping Pill, a herbal medicine aimed at cardiovascular ailments, a testament to the company's commitment to merging ancient remedies with modern health solutions. By establishing an extensive distribution network both domestically and internationally, Tasly ensures its unique offerings reach a wide audience, catering not only to China's growing appetite for health products but also tapping into global markets hungry for alternative medicine solutions. Tasly’s financial engine leverages its broad spectrum of offerings, driven by both consumer demand for TCM and the pharmaceutical industry's appetite for innovation. The company invests significantly in research and development, with a particular emphasis on internationalizing TCM and obtaining global recognition for its products through clinical trials and partnerships. Such strategic actions bolster its competitive edge, positioning Tasly as a leader in an industry where tradition and science converge. Revenue streams are further diversified by the company's health management services and a growing footprint in biotechnology, showcasing its adaptability and forward-thinking approach. This intricate ballet of innovation and tradition enables Tasly Pharmaceutical Group to not just survive but thrive in an industry characterized by rapid advancements and shifting consumer paradigms.

Intrinsic Value
20.28 CNY
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Tasly Pharmaceutical Group Co Ltd's Minority Interest?
Minority Interest
311.9m CNY

Based on the financial report for Sep 30, 2024, Tasly Pharmaceutical Group Co Ltd's Minority Interest amounts to 311.9m CNY.

What is Tasly Pharmaceutical Group Co Ltd's Minority Interest growth rate?
Minority Interest CAGR 10Y
3%

Over the last year, the Minority Interest growth was -2%. The average annual Minority Interest growth rates for Tasly Pharmaceutical Group Co Ltd have been -10% over the past three years , -16% over the past five years , and 3% over the past ten years .

Back to Top